HIV Rapid Test Kits Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2023 – 2032

HIV Rapid Test Kits Market size is anticipated to depict substantial growth from 2023 to 2032 led by the rising incidences of the human immunodeficiency virus (HIV) infection.
 

In the past decade, HIV cases have increased dramatically accounting for a large share of global morbidity and mortality. According to the World Health Organization (WHO), in 2021, more than 650,000 people worldwide died due to HIV-related causes, while over 1.5 million individuals acquired the HIV infection.
 

Moreover, the increasing focus on point-of-care testing across healthcare facilities for early diagnosis and treatment of HIV infections will complement the industry outlook. POCs are gaining widespread demand among both patients and medical professionals as they allow efficient management of high-risk patient pools with minimal maintenance and easy operation.
 

The COVID-19 pandemic also made way for multiple mobile health trends that are expected to transform the HIV testing and treatment landscape with an increasing inclination towards at-home HIV tests. The influx of several global initiatives catering to the unmet testing needs will further boost the adoption of HIV rapid test kits.
 

However, the Russia-Ukraine war is expected to have a dramatic impact on the HIV rapid test kits industry due to severe supply chain disruptions. Several biopharmaceutical companies have ceased clinical research, R&D activities and scientific studies in Ukraine in light of the war. For instance, in March 2022, Aeterna Zentaris announced plans to delay recruitment for the ongoing phase 3 trial of children in 2023.  
 

Based on principle, the HIV rapid test kits market share from NAAT HIV rapid test kits will depict a notable rise by 2032, powered by the rapid adoption of the technology to offer high sensitivity, and specificity. Leading health agencies, including the WHO are increasingly deploying NAAT as the key tool for the detection of different infections such as HIV, thus encouraging the product adoption.
 

In terms of sample type, the consumption of HIV rapid test kits to test blood samples is expected to increase significantly through 2032 due to the rising high-specificity requirements in detecting blood samples for pathogens. The widespread availability of HIV rapid test kits that employ blood specimens for the diagnosis of infections will complement the industry outlook.
 

HIV rapid test kits market from the hospital segment is estimated to account for a notable revenue share by 2032. Rapid influx of investments in the healthcare infrastructure is accelerating the development of advanced medical facilities. The emergence of novel epidemics and pandemics, and the growing intervention of several governments towards improving access to healthcare services will also drive the industry trends.
 

North America HIV rapid test kits market size is estimated to expand at a substantial rate between 2023-2032 led by the solid footprint of key manufacturers in the U.S., and Canada. The region is also experiencing a rise in the number of HIV infection cases, which is expected to propel the demand for rapid test kits. According to HIV.gov, nearly 1.2 million Americans have HIV, and approximately 13% of them remain unaware and need testing.
 

The competitive landscape of the HIV rapid test kits market includes players, such as bioMérieux, Biosynex, Atomo Diagnostics, OraSure Technologies, Chembio Diagnostic Systems, Sedia Biosciences Corporation, Biolytical Laboratories, Abbott, BioSure, and Hologic among others. These companies are developing novel products to address the thriving patient needs. For instance, in November 2022, Chembio Diagnostics applied for a CLIA waiver to the U.S. FDA for its DPP HIV-Syphilis System.
 

What Information does this report contain?